OA10.04 Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study
Lau, S., Ahn, M.-J., Moskovitz, M., Pogorzelski, M., Haefliger, S., Paulson, K.G., Parkes, A., Zhang, Y., Hamidi, A., Wermke, M.
Published in Journal of thoracic oncology (01.10.2024)
Published in Journal of thoracic oncology (01.10.2024)
Get full text
Journal Article